Limb spasticity
Limb spasticity is an abnormal increase in muscle resistance that becomes more pronounced when a limb is moved quickly. It results from damage to the brain or spinal cord and may follow stroke, cerebral palsy, traumatic brain injury, multiple sclerosis, or other central nervous system disorders. The resulting muscle overactivity can interfere with comfort, hygiene, dressing, hand use, positioning, walking, or caregiving.
Botulinum toxin can reduce overactivity in selected muscles, but lower muscle tone is not automatically the same as better function. Weakness, impaired motor control, pain, joint stiffness, and fixed contracture may also determine what a person can do.
Spasticity is only one part of the movement problem
Section titled “Spasticity is only one part of the movement problem”| Finding | Why it changes interpretation |
|---|---|
| Dynamic muscle overactivity | A selected muscle may be a reasonable treatment target when its overactivity contributes to a defined problem. |
| Fixed contracture | Structural shortening or joint restriction may remain even when muscle overactivity is reduced. |
| Existing weakness | Additional weakening can trade lower tone for worse grip, transfers, stance, or gait. |
| Impaired selective motor control | A limb may remain difficult to use even after passive movement becomes easier. |
| Pain, skin injury, or care difficulty | Comfort, positioning, hygiene, splint tolerance, and ease of care may be meaningful goals even without improved active movement. |
The U.S. BOTOX label explicitly notes that treatment has not been shown to improve upper-extremity functional abilities or range of motion at a joint affected by fixed contracture. This limitation illustrates why tone scores alone do not establish practical benefit.
Current U.S. product scope
Section titled “Current U.S. product scope”| Product | U.S. limb-spasticity scope | Important boundary |
|---|---|---|
| BOTOX (onabotulinumtoxinA) | Spasticity in patients aged 2 years and older, with adult and pediatric upper- and lower-limb dosing sections | The label includes the functional and fixed-contracture limitation described above. |
| DYSPORT (abobotulinumtoxinA) | Spasticity in patients aged 2 years and older, with adult and pediatric upper- and lower-limb dosing sections | Its units and dosing framework are specific to DYSPORT. |
| XEOMIN (incobotulinumtoxinA) | Upper-limb spasticity in patients aged 2 years and older | The current U.S. indication does not extend to lower-limb spasticity. |
This table describes label scope, not equivalence or a treatment ranking. A product approved for one limb or age group should not be assumed to carry the same authorization elsewhere.
Treatment goals determine whether a response matters
Section titled “Treatment goals determine whether a response matters”Clinical studies and practice may assess several different outcome domains:
| Outcome domain | Examples of a meaningful change |
|---|---|
| Muscle overactivity | Less resistance to passive movement or fewer involuntary postures |
| Passive function | Easier palm cleaning, dressing, positioning, splinting, or caregiving |
| Active function | Improved reaching, grasping, releasing, standing, or walking when sufficient motor control remains |
| Symptoms and tissue protection | Less pain, fewer pressure or skin problems, or better comfort |
| Individual goal attainment | Progress toward a specific activity or care goal agreed before treatment |
Reviews of post-stroke upper-limb treatment distinguish passive benefits from active functional gains and emphasize goal selection. This is why a useful assessment starts with the problem caused by a particular posture or muscle pattern rather than with a generic objective to “reduce tone.”
Upper limb, lower limb, adult, and pediatric care are distinct
Section titled “Upper limb, lower limb, adult, and pediatric care are distinct”Upper-limb treatment may address a clenched fist, flexed wrist or elbow, shoulder posture, pain, or difficulty with hygiene and dressing. Lower-limb treatment may focus on foot position, shoe wear, bracing, standing, transfers, or gait. The balance between useful tone and unwanted weakness is different in each task.
Pediatric treatment also occurs within growth, development, orthotic management, rehabilitation, and sometimes surgical planning. Product labeling and the boxed warning require particular attention because distant spread of toxin effect has been reported most often in children treated for spasticity.
Safety interpretation
Section titled “Safety interpretation”Relevant risks include excessive local weakness, pain, falls or loss of a useful compensatory pattern, and class-wide symptoms consistent with spread of toxin effect, including swallowing or breathing difficulty. Risk assessment changes with the muscles treated, total exposure, underlying neuromuscular or respiratory vulnerability, and the person’s baseline mobility.
Anatomical targeting, product-specific dosing, and follow-up should therefore remain tied to an explicit functional or care goal. See Dose interpretation, How anatomy changes botulinum toxin interpretation, and Safety and adverse-effect interpretation.
Related topics
Section titled “Related topics”References
Section titled “References”- U.S. National Library of Medicine. BOTOX prescribing information 🔗.
- U.S. National Library of Medicine. DYSPORT prescribing information 🔗.
- U.S. National Library of Medicine. XEOMIN prescribing information 🔗.
- Andringa A, et al. Effectiveness of botulinum toxin treatment for upper limb spasticity poststroke over different ICF domains: a systematic review and meta-analysis 🔗. Archives of Physical Medicine and Rehabilitation. 2019.
- Baker JA, Pereira G. The efficacy of botulinum toxin A for spasticity and pain in adults: a systematic review and meta-analysis using the grades of recommendation, assessment, development and evaluation approach 🔗. Clinical Rehabilitation. 2013.